Published in J Virol on February 01, 1996
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J (1998) 3.30
Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J Virol (1996) 3.19
Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release. J Virol (2000) 2.97
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1999) 2.08
Characterization of Rous sarcoma virus Gag particles assembled in vitro. J Virol (2001) 1.85
Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein. Proc Natl Acad Sci U S A (2002) 1.76
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Rous sarcoma virus Gag protein-oligonucleotide interaction suggests a critical role for protein dimer formation in assembly. J Virol (2002) 1.56
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
Characterization of human immunodeficiency virus type 1 matrix revertants: effects on virus assembly, Gag processing, and Env incorporation into virions. J Virol (1997) 1.40
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33
The transdominant endogenous retrovirus enJS56A1 associates with and blocks intracellular trafficking of Jaagsiekte sheep retrovirus Gag. J Virol (2006) 1.23
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol (2000) 1.18
A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions. J Virol (2000) 1.16
Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents. Proc Natl Acad Sci U S A (1997) 1.15
Detailed mapping of the nuclear export signal in the Rous sarcoma virus Gag protein. J Virol (2005) 1.08
Analysis of bovine leukemia virus gag membrane targeting and late domain function. J Virol (2002) 1.07
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
trans-acting inhibition of genomic RNA dimerization by Rous sarcoma virus matrix mutants. J Virol (2001) 1.05
Role of the human T-cell leukemia virus type 1 PTAP motif in Gag targeting and particle release. J Virol (2006) 1.04
Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission. J Virol (1999) 1.03
Rous sarcoma virus gag has no specific requirement for phosphatidylinositol-(4,5)-bisphosphate for plasma membrane association in vivo or for liposome interaction in vitro. J Virol (2011) 1.02
Overlapping roles of the Rous sarcoma virus Gag p10 domain in nuclear export and virion core morphology. J Virol (2007) 1.00
Retroviral matrix and lipids, the intimate interaction. Retrovirology (2011) 0.96
Effect of multimerization on membrane association of Rous sarcoma virus and HIV-1 matrix domain proteins. J Virol (2013) 0.93
Intermolecular interactions between retroviral Gag proteins in the nucleus. J Virol (2007) 0.92
Specificity of plasma membrane targeting by the rous sarcoma virus gag protein. J Virol (2003) 0.90
The roles of lipids and nucleic acids in HIV-1 assembly. Front Microbiol (2014) 0.89
Transport of the intracisternal A-type particle Gag polyprotein to the endoplasmic reticulum is mediated by the signal recognition particle. J Virol (2003) 0.87
PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells. J Virol (2001) 0.87
The major site of phosphorylation within the Rous sarcoma virus MA protein is not required for replication. J Virol (1998) 0.84
Characterization of producer cell-dependent restriction of murine leukemia virus replication. J Virol (2002) 0.82
Splicing factor hSlu7 contains a unique functional domain required to retain the protein within the nucleus. Mol Biol Cell (2004) 0.80
Mechanistic differences between nucleic acid chaperone activities of the Gag proteins of Rous sarcoma virus and human immunodeficiency virus type 1 are attributed to the MA domain. J Virol (2014) 0.80
Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol (1987) 66.52
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Integration of murine leukemia virus DNA depends on mitosis. EMBO J (1993) 7.62
Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail. Cell (1977) 7.23
Generation of avian myeloblastosis virus structural proteins by proteolytic cleavage of a precursor polypeptide. J Mol Biol (1975) 6.84
The biology and enzymology of eukaryotic protein acylation. Annu Rev Biochem (1988) 6.83
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol (1994) 6.60
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A (1993) 6.44
An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol (1989) 4.60
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell (1995) 4.41
Lipid asymmetry in membranes. Annu Rev Biochem (1979) 4.39
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25
Myristylation and palmitylation of Src family members: the fats of the matter. Cell (1994) 4.21
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Binding of acylated peptides and fatty acids to phospholipid vesicles: pertinence to myristoylated proteins. Biochemistry (1993) 3.63
Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J Mol Biol (1994) 3.56
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions. J Virol (1987) 3.28
A radiological study of cell-virus interaction in the Rous sarcoma. Virology (1959) 3.24
The first seven amino acids encoded by the v-src oncogene act as a myristylation signal: lysine 7 is a critical determinant. Mol Cell Biol (1988) 3.24
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Structural similarity between the p17 matrix protein of HIV-1 and interferon-gamma. Nature (1994) 2.35
Binding of peptides with basic residues to membranes containing acidic phospholipids. Biophys J (1991) 2.30
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Assembly of phospholipids into cellular membranes: biosynthesis, transmembrane movement and intracellular translocation. Annu Rev Cell Biol (1988) 2.14
Amino-terminal basic residues of Src mediate membrane binding through electrostatic interaction with acidic phospholipids. Proc Natl Acad Sci U S A (1994) 2.12
Replication-competent retrovirus vectors for the transfer and expression of gene cassettes in avian cells. J Virol (1991) 1.95
Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science (1990) 1.93
Structure and processing of the p2 region of avian sarcoma and leukemia virus gag precursor polyproteins. J Virol (1986) 1.93
A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol (1992) 1.80
Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation. J Virol (1995) 1.73
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
RNA-binding properties of the matrix protein (p19gag) of avian sarcoma and leukemia viruses. J Virol (1990) 1.59
Lysine residues form an integral component of a novel NH2-terminal membrane targeting motif for myristylated pp60v-src. J Cell Biol (1992) 1.53
Assembly of the matrix protein of simian immunodeficiency virus into virus-like particles. Virology (1993) 1.52
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage. J Virol (1992) 1.50
Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses. J Virol (1995) 1.45
trans-acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase. J Virol (1991) 1.45
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
Interaction of tyrosine kinase oncoproteins with cellular membranes. Biochim Biophys Acta (1993) 1.33
Binding of basic peptides to acidic lipids in membranes: effects of inserting alanine(s) between the basic residues. Biochemistry (1992) 1.26
HIV-1 matrix protein p17 resides in cell nuclei in association with genomic RNA. AIDS Res Hum Retroviruses (1992) 1.17
Amino-terminal amino acid sequence of p10, the fifth major gag polypeptide of avian sarcoma and leukemia viruses. J Virol (1983) 1.04
Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med (1978) 11.99
The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A (2000) 9.67
A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity (2001) 9.45
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature (1999) 8.50
The Raji cell radioimmune assay for detecting immune complexes in human sera. J Clin Invest (1976) 8.06
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87
Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. J Exp Med (1980) 5.23
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med (1980) 4.90
DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol (1982) 4.64
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg (1978) 4.55
Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature (1992) 4.46
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. Nat Immunol (2001) 3.89
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging. J Virol (2000) 3.54
Endogenous oncornaviral gene expression in adult and fetal mice: quantitative, histologic, and physiologic studies of the major viral glycorprotein, gp70. J Exp Med (1976) 3.51
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics (1980) 3.21
Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J Virol (1996) 3.19
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids. J Biol Chem (2000) 3.18
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
WW domains and retrovirus budding. Nature (1996) 3.10
Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int (1973) 3.09
Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet (1976) 3.00
Diagnosis and management of pituitary abscess: a review of twenty-four cases. J Neurosurg (2001) 3.00
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90
Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol (2001) 2.86
Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains. J Virol (2001) 2.82
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J Neurosci (2001) 2.75
Mechanism and modification of rejection of heterografts between divergent species. Transplant Proc (1970) 2.63
Repetitive DNA of Candida albicans: nuclear and mitochondrial components. J Bacteriol (1984) 2.52
Binding of soluble immune complexes to human lymphoblastoid cells. II. Use of Raji cells to detect circulating immune complexes in animal and human sera. J Exp Med (1974) 2.51
Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol (1988) 2.47
Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest (1981) 2.41
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg (1977) 2.39
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Humoral antibodies and coagulation mechanisms in the accelerated or hyperacute rejection of renal homografts in sensitized canine recipients. Surgery (1970) 2.38
Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection. N Engl J Med (1970) 2.33
Highly specific antibody to Rous sarcoma virus src gene product recognizes a novel population of pp60v-src and pp60c-src molecules. J Cell Biol (1985) 2.32
Vanadate inhibits the red cell (Na+, K+) ATPase from the cytoplasmic side. Nature (1978) 2.27
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol (2001) 2.24
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Endovascular and surgical treatment of unruptured cerebral aneurysms: comparison of risks. Ann Neurol (2000) 2.20
Antitubular basement-membrane antibodies in methicillin-associated interstitial nephritis. N Engl J Med (1974) 2.20
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
Amino-terminal basic residues of Src mediate membrane binding through electrostatic interaction with acidic phospholipids. Proc Natl Acad Sci U S A (1994) 2.12
Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates. J Virol (2000) 2.11
Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol (1998) 2.11
Ceftizoxime versus vancomycin and gentamicin in neurosurgical prophylaxis: a randomized, prospective, blinded clinical study. Neurosurgery (1993) 2.10
Diagnosis of immunopathologic renal disease. Kidney Int (1974) 2.07
Meningiomas induced by high-dose cranial irradiation. J Neurosurg (1993) 2.05
Decreased production of interferon-gamma by human neonatal cells. Intrinsic and regulatory deficiencies. J Clin Invest (1986) 2.05
In vivo clonogenic tumor cell kinetics following 1,3-bis(2-chloroethyl)-1-nitrosourea brain tumor therapy. Cancer Res (1976) 2.04
Rapid plasma membrane anchoring of newly synthesized p59fyn: selective requirement for NH2-terminal myristoylation and palmitoylation at cysteine-3. J Cell Biol (1997) 2.03
Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet (1995) 2.03
Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg (1994) 2.00
Membrane binding of myristylated peptides corresponding to the NH2 terminus of Src. Biochemistry (1994) 1.99
An evaluation of elution techniques in the study of immune complex glomerulonephritis. J Immunol (1977) 1.96
Antigen quantitation in experimental immune complex glomerulonephritis. I. Acute serum sickness. J Immunol (1970) 1.93
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
Intracellular trafficking of the UL11 tegument protein of herpes simplex virus type 1. J Virol (2001) 1.90
Dual myristylation and palmitylation of Src family member p59fyn affects subcellular localization. J Biol Chem (1994) 1.90
Normal perfusion pressure breakthrough theory. Clin Neurosurg (1978) 1.87
Epidermoid cysts of the posterior fossa. J Neurosurg (1985) 1.85
Surgical treatment of syringomyelia. Favorable results with syringoperitoneal shunting. J Neurosurg (1984) 1.84
Circular mitochondrial genome of Candida albicans contains a large inverted duplication. J Bacteriol (1985) 1.84
Lung antibacterial defense mechanisms in infant and adult rats: implications for the pathogenesis of group B streptococcal infections in the neonatal lung. J Infect Dis (1988) 1.82
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep (1983) 1.81
Regulation of pp56lck during T-cell activation: functional implications for the src-like protein tyrosine kinases. EMBO J (1987) 1.80
Biochemical characterization of a palmitoyl acyltransferase activity that palmitoylates myristoylated proteins. J Biol Chem (1995) 1.79
Electrostatics and the membrane association of Src: theory and experiment. Biochemistry (1998) 1.78
Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int (1987) 1.78
In vitro synthesis of pp60v-src: myristylation in a cell-free system. Mol Cell Biol (1988) 1.77
T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol (2000) 1.76
Reduced interferon-gamma mRNA levels in human neonates. Evidence for an intrinsic T cell deficiency independent of other genes involved in T cell activation. J Exp Med (1986) 1.75
Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med (1971) 1.74
The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg (1990) 1.72
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
Current multimodality management of infectious intracranial aneurysms. Neurosurgery (2001) 1.68
Restricted production of interleukin 4 by activated human T cells. Proc Natl Acad Sci U S A (1988) 1.67
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery (1998) 1.66
Detection of circulating immune complexes in patients with glomerulonephritis. Kidney Int (1977) 1.66
Modulation of neutrophil influx in glomerulonephritis in the rat with anti-macrophage inflammatory protein-2 (MIP-2) antibody. J Clin Invest (1995) 1.65
Cellular and molecular mechanisms for reduced interleukin 4 and interferon-gamma production by neonatal T cells. J Clin Invest (1991) 1.64
Role for endogenous and acquired peroxidase in the toxoplasmacidal activity of murine and human mononuclear phagocytes. J Clin Invest (1982) 1.64
Heterogeneous fatty acylation of Src family kinases with polyunsaturated fatty acids regulates raft localization and signal transduction. J Biol Chem (2001) 1.63
Activity of human blood leukocytes against Toxoplasma gondii. J Infect Dis (1979) 1.63
Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest (1995) 1.62